Abstract
A randomised, double blind, parallel groups, placebo controlled clinical trial was
conducted to assess the efficacy and safety profile of 250 mg ascorbic acid (Vit.
C, Vagi C®) in women with bacterial vaginosis (BV). Overall, 277 out-patients with
at least three of the following signs (white discharge that smoothly coats the vaginal
walls, pH of vaginal fluid >4.5, a fishy odour of vaginal discharge before or after
addition of 10% KOH and presence of clue cells on microscopic examination) were randomised
to apply a tablet deeply into the vagina once daily for 6 days. The primary efficacy
endpoint was the cure rate, defined as the recovery of all inclusion criteria. In
the intent-to-treat (ITT) population, cure was achieved by 55.3 % of patients with
Vit. C (n = 141) and by 25.7 % of patients with placebo (n = 136). The between-group
difference was 29.6 % (p < 0.001). In the per-protocol (PP) population, cure rate
was 66.4 % with Vit. C (n = 116) and 27.1 % with placebo (n = 118), respectively.
Between-group difference was 39.3 % (p < 0.001). In a subset of patients with centralised
evaluation of the vaginal swab, cure in ITT was achieved by 86.3 % of patients with
Vit. C (n = 51) and by 7.6 % of patients with placebo (n = 53), the between-group
difference was 78.7 % (p < 0.0001). Cure rate in PP was 86.0 % with Vit. C (n = 50)
and 6.1 % with placebo (n = 49), between-group difference was 79.9 % (p < 0.0001).
Both Vit. C and placebo were well tolerated and no differences in safety profile were
evident between groups.
The results support an effective and safe use of silicon-coated Vit. C vaginal tablets
in the management of BV.
Key words
Ascorbic acid vaginal tablets - Bacterial vaginosis - Vaginal pH - Vitamin C vaginal
tablets
